|
EP0656947A1
(en)
|
1992-08-21 |
1995-06-14 |
Schering Corporation |
Human interleukin-13
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
FR2742156A1
(fr)
|
1995-12-06 |
1997-06-13 |
Sanofi Sa |
Polypeptide recepteur de l'il-13
|
|
US6335426B1
(en)
*
|
1996-06-14 |
2002-01-01 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6028176A
(en)
*
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
|
US6673602B1
(en)
|
1999-06-11 |
2004-01-06 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
|
US6737511B1
(en)
|
1999-08-16 |
2004-05-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
|
|
JP4505166B2
(ja)
|
1999-09-09 |
2010-07-21 |
シェーリング コーポレイション |
哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
|
|
JP2003511019A
(ja)
|
1999-10-06 |
2003-03-25 |
ザ ペン ステート リサーチ ファウンデーション |
Ｉｌ１３変異体
|
|
WO2001034645A2
(en)
|
1999-11-11 |
2001-05-17 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated il-13 molecules and their uses
|
|
GB0004016D0
(en)
|
2000-02-22 |
2000-04-12 |
Royal Brompton Hospital |
Biological material and uses thereof
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
JP4863150B2
(ja)
|
2000-08-30 |
2012-01-25 |
ザ・ペン・ステート・リサーチ・ファンデーション |
インターロイキン１３のアミノ酸置換変異体
|
|
AU2440802A
(en)
|
2000-10-18 |
2002-04-29 |
Massachusetts Inst Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
US20030013851A1
(en)
|
2001-06-07 |
2003-01-16 |
Robert Powers |
Solution structure of IL-13 and uses thereof
|
|
US20040248260A1
(en)
|
2001-10-26 |
2004-12-09 |
Heavner George A. |
IL-13 mutein proteins, antibodies, compositions, methods and uses
|
|
JP2008526889A
(ja)
|
2005-01-10 |
2008-07-24 |
リサーチ ディベロップメント ファウンデーション |
癌治療のための標的化キメラ分子
|
|
AU2006347606B2
(en)
|
2005-09-09 |
2012-10-11 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for inhibiting cell death or enhancing cell proliferation
|
|
US20070160658A1
(en)
|
2005-10-20 |
2007-07-12 |
The Penn State Research Foundation |
Delivery system for diagnostic and therapeutic agents
|
|
CA2654292C
(en)
|
2006-06-07 |
2022-01-11 |
Genzyme Corporation |
Gene therapy for motor neuron disorders
|
|
WO2008101671A2
(en)
|
2007-02-19 |
2008-08-28 |
Apogenix Gmbh |
Il-4 fc fusion proteins
|
|
CA2697529A1
(en)
|
2007-08-24 |
2009-03-05 |
Regents Of The University Of Minnesota |
Receptor-targeting reagents
|
|
JP5997443B2
(ja)
|
2008-05-16 |
2016-09-28 |
バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ |
標的化凝固因子およびそれを使用する方法
|
|
EP2352526A1
(en)
|
2008-09-19 |
2011-08-10 |
Protox Therapeutics Inc. |
Treating cancer stem cells using targeted cargo proteins
|
|
US20100183545A1
(en)
|
2008-10-14 |
2010-07-22 |
The United States Of America, As Represented By The Secretary, |
Targeted cargo protein combination therapy
|
|
JP2010154842A
(ja)
|
2008-12-03 |
2010-07-15 |
Koji Kawakami |
Ｅｇｆｒを標的にした新規抗がんキメラペプチド
|
|
US20110023680A1
(en)
|
2009-07-30 |
2011-02-03 |
Kuo-Chung Wang |
Pcb cutter module with detachable cutters
|
|
TWI397428B
(zh)
|
2009-12-29 |
2013-06-01 |
Ind Tech Res Inst |
標的第四介白素受體之傳輸系統
|
|
WO2011106779A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Aerovance Inc. |
Use of modified il-4 mutien receptor antagonists to treat dermatitis
|
|
JP5734951B2
(ja)
|
2010-03-03 |
2015-06-17 |
シャープ株式会社 |
表示装置およびその駆動方法、ならびに液晶表示装置
|
|
EP2629788A4
(en)
|
2010-10-22 |
2014-03-19 |
Protox Therapeutics Corp |
USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
WO2012139112A1
(en)
|
2011-04-08 |
2012-10-11 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
|
|
US10548921B2
(en)
|
2011-04-08 |
2020-02-04 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
EP2850093B1
(en)
|
2012-01-27 |
2019-01-09 |
The Board of Trustees of the Leland Stanford Junior University |
Therapeutic il-13 polypeptides
|
|
US10781242B2
(en)
|
2013-09-24 |
2020-09-22 |
Medicenna Therapeutics Inc. |
Interleukin-2 fusion proteins and uses thereof
|
|
EP3049526B1
(en)
|
2013-09-24 |
2021-02-24 |
Medicenna Therapeutics, Inc. |
Interleukin-4 receptor-binding fusion proteins and uses thereof
|
|
US9975942B2
(en)
|
2013-11-11 |
2018-05-22 |
Wake Forest University Health Services |
EPHA3 And multi-valent targeting of tumors
|
|
KR102480433B1
(ko)
|
2014-02-07 |
2022-12-21 |
맥마스터 유니버시티 |
3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
|
|
JP2017527310A
(ja)
|
2014-09-09 |
2017-09-21 |
ユーナム・セラピューティクスＵｎｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ |
キメラ受容体および免疫療法におけるその使用
|
|
AU2015317351B2
(en)
|
2014-09-19 |
2020-07-02 |
City Of Hope |
Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
|
|
SG11201704519YA
(en)
|
2014-12-02 |
2017-07-28 |
Roger Williams Hospital |
Methods and compositons for treating cancer
|
|
MA43859A
(fr)
|
2016-01-11 |
2018-11-21 |
Novartis Ag |
Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
|
|
WO2018112266A1
(en)
|
2016-12-14 |
2018-06-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
WO2019051204A1
(en)
|
2017-09-08 |
2019-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
|
|
EP3694558B1
(en)
|
2017-10-10 |
2024-04-10 |
Medicenna Therapeutics Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
|
CA3129200A1
(en)
|
2019-02-07 |
2020-08-13 |
Medicenna Therapeutics, Inc. |
Il-4r as a biomarker in cancer
|
|
CN116390744A
(zh)
|
2020-06-24 |
2023-07-04 |
梅迪塞纳医疗股份有限公司 |
双功能性超级因子及其用途
|